Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Br J Cancer. 2016 Jun 14;114(12):e21.
doi: 10.1038/bjc.2016.133.
Epub 2016 May 26.